These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2057915)

  • 21. [Heterogeneity of mammalian antithrombin III].
    Bashkov GV; Kalishevskaia TM; Strukova SM
    Biokhimiia; 1989 Nov; 54(11):1797-803. PubMed ID: 2627551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-association of antithrombin III relates to multimer formation of thrombin-antithrombin III complexes.
    Preissner KT
    Thromb Haemost; 1993 May; 69(5):422-9. PubMed ID: 8322264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lysine binding sites of human plasminogen. Evidence for a critical tryptophan in the binding site of kringle 4.
    Hochschwender SM; Laursen RA
    J Biol Chem; 1981 Nov; 256(21):11172-6. PubMed ID: 6793592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
    de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Sixma JJ; Bouma BN
    Thromb Haemost; 1984 Aug; 52(1):66-70. PubMed ID: 6495266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antithrombin III activity in relation to multiple administration of various doses of heparin to normal animals].
    Kudriashov BA; Pastorova VE; Liapina LA
    Vopr Med Khim; 1985; 31(3):37-41. PubMed ID: 4024529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes.
    Tyler-Cross R; Sobel M; McAdory LE; Harris RB
    Arch Biochem Biophys; 1996 Oct; 334(2):206-13. PubMed ID: 8900394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-specific influence of chemical modification upon the properties of antithrombin III:modification of carboxyl groups.
    Scully MF; Kakkar VV; Goodwin CA
    Thromb Res; 1992 Aug; 67(4):447-56. PubMed ID: 1412223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.
    Howarth DJ; Samson D; Stirling Y; Seghatchian MJ
    Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Abnormal antithrombin III: abnormalities of heparin or protease binding domain].
    Sakuragawa N; Niiya K; Takahashi K; Hayashi T; Oguma Y; Saitoh S
    Rinsho Byori; 1993 May; 41(5):492-505. PubMed ID: 8350512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism.
    Owen MC; George PM; Lane DA; Boswell DR
    FEBS Lett; 1991 Mar; 280(2):216-20. PubMed ID: 2013315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence that arginine-129 and arginine-145 are located within the heparin binding site of human antithrombin III.
    Sun XJ; Chang JY
    Biochemistry; 1990 Sep; 29(38):8957-62. PubMed ID: 2271571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylation of antithrombin III by aspirin.
    Villanueva GB; Allen N
    Semin Thromb Hemost; 1986 Jul; 12(3):213-5. PubMed ID: 3095926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refolding properties of antithrombin III. Mechanism of binding to heparin.
    Villanueva GB; Allen N
    J Biol Chem; 1983 Nov; 258(22):14048-53. PubMed ID: 6643466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The heparin binding site of human antithrombin III. Selective chemical modification at Lys114, Lys125, and Lys287 impairs its heparin cofactor activity.
    Liu CS; Chang JY
    J Biol Chem; 1987 Dec; 262(36):17356-61. PubMed ID: 3121595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombin inactivation by neutrophil elastase requires heparin.
    Jordan RE; Nelson RM; Kilpatrick J; Newgren JO; Esmon PC; Fournel MA
    Am J Med; 1989 Sep; 87(3B):19S-22S. PubMed ID: 2801725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence by chemical modification for the involvement of one or more tryptophanyl residues of bovine antithrombin in the binding of high-affinity heparin.
    Björk I; Nordling K
    Eur J Biochem; 1979 Dec; 102(2):497-502. PubMed ID: 527591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mechanism for heparin-induced potentiation of antithrombin III.
    van Boeckel CA; Grootenhuis PD; Visser A
    Nat Struct Biol; 1994 Jul; 1(7):423-5. PubMed ID: 7664058
    [No Abstract]   [Full Text] [Related]  

  • 39. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135.
    Brennan SO; George PM; Jordan RE
    FEBS Lett; 1987 Jul; 219(2):431-6. PubMed ID: 3609301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure to solvent of tyrosyl and tryptophanyl residues of bovine antithrombin in the absence and presence of high-affinity and low-affinity heparin.
    Björk I; Larsson K
    Biochim Biophys Acta; 1980 Feb; 621(2):273-82. PubMed ID: 7353045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.